TRIAL DETAIL

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Drug:
Trial Name:
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Withdrawn
Phase:
2
Start Date 01/01/2017
Age of Trial (yrs) 7.2
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + MEK inhibitor
Strategy:
Block KIT + Block related tumor signal paths
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
SARC029
Sponsor:
Sarcoma Aliance for Research through Collaboration
Patient Contact:
SARC OFFICE 734-930-7600 SARC029@sarctrials.org
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Detailed Description:
Trametinib and pazopanib are independently approved for other cancers. Both drugs work to inhibit tumor development in different ways. Combining these drugs may lead to improved disease control. The purpose of this study is to evaluate the effect of the combination of both drugs on advanced gastrointestinal stromal tumors.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Palo Alto
CA
94304
USA